WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Alma
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
PharmaTimes Media Ltd | July 05, 2017
In big news for Northern Ireland-headquartered drug discovery group Almac, US regulators have awarded orphan drug status to the firm’s experimental therapy for ovarian cancer. ALM201 is a first-in-class therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL, known to have an effect on a number of important tumour biology processes, including cancer stem cells and angiogenesis....
Trifecta Pharmaceuticals | April 08, 2019
FORT LAUDERDALE, FL, UNITED STATES, April 8, 2019 /EINPresswire.com/ -- TRIFECTAPHARMACEUTICALS USA, a leading developer, manufacturer and distributor of specialty OTC topical ointments, creams and gels, today announces its inaugural distribution partnership with Walmart. Mayinglong hemorrhoid ointment, a known and trusted treatment for the pain and discomfort associated with hemorrhoids, will be available on Walmart’s shelves from April 2019. Mayinglong hemorrhoid ointment combines popula...
fiercepharma | May 31, 2018
Want to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing.On Thursday, the big biotech said it had brought on Pfizer veteran Dan Karp as its EVP of corporate development, ending his stint as the pharma giant’s VP of worldwide business development and head of R&D business development. For Biogen, Karp will lead a newly minted “corporate development function,” spanning business development and ...
Questex LLC | December 04, 2018
Litigation is growing over tainted blood pressure medications with a class-action lawsuit now filed in Florida against Walmart and three drug companies that span the supply chain. In addition to the retailer, the lawsuit names Indian drugmaker Aurobindo, U.S. drugmaker ScieGen Pharmaceuticals and distributor Westminster Pharmaceuticals. It was filed in federal court in Florida against the four over the sale of irbesartan because the drug contained the impurity, N nitrosodiethylamine (NDEA). The ...
PHARMACY MARKET
Article
Pharma Tech
Video
Pharmacy Market
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE